Visus Therapeutics is coming for AbbVie. After ceding a big head start to AbbVie’s recently approved Vuity, Visus has posted midphase data that advance its effort to come from behind in the new market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results